



## Transforming with science and technology

**Innovation | Excellence | Sustainability**

Science and technology form the backbone of pharma manufacturing. At Granules India, our spirit of innovation is helping take the business to the next level. Technology will play a critical role in enhancing and optimising capacities, capabilities, processes and quality standards while ensuring cost efficiency for the business and our customers. Extensive and advanced level research and development will keep our product pipeline robust with a diverse range of cost-effective offerings. Excellence is a moving target at Granules. This means that we are continuously calibrating our core and strengthening strategies to deliver more. To become a business that stands for more than profitability and helps create positive impact in the industry, we are adopting and embedding sustainable practices across our operations. Our core focus remains on transforming with times and to this end, we will continue to overrule the status quo and think anew.



# FY 2021-22 Highlights



## Operational

- Granules has the highest generic prescription in terms of absolute growth 17.8% in the US market
- 6 ANDA approvals from USFDA, and additional approvals for 1 EU dossier and 2 Canadian dossiers
- Launched 24 generic products under GPI label in US
- Filed 2 patents in India directed towards new process for manufacturing intermediates and /or APIs, purification and pharmaceutical composition thereof
- USFDA approval for generic Prazosin Hydrochloride capsules used for the treatment of high blood pressure



## Financial

**₹ 3,76,492 Lakhs**  
Income from Operations

**₹ 72,223 Lakhs**  
EBITDA

**19.2%**  
EBITDA Margins

**₹ 41,276 Lakhs**  
PAT

**₹ 16.66**  
EPS

**1.64**  
Asset Turnover



## Environmental

**3,72,589 KL**  
Water consumption

**76,25,239 kwh**  
Renewable energy share

**81,111 KL**  
Recycled water used



## Social

**10%**  
Women employees

**68%**  
Permanent workforce

**₹ 9.13 Cr**  
CSR expenditure



## Governance

**100%**  
Shareholder Grievance Resolved

**98%**  
Average board meeting attendance

**50%**  
Independent directors on board